"Due to the timing of diagnosis during this critical period of physical, intellectual, and psychosocial development, the higher rate of colectomy, and their longer lifespan without a colon, it is ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Crohn’s and UC affect the GI tract differently. Crohn’s impacts the whole tract, while UC is limited to the colon. Learn the ...

Johnson & Johnson has reported new long‑term results from the QUASAR long‑term extension study, showing that Tremfya (guselkumab) sustained clinical, endoscopic and histologic outcomes through week ...

Greater access to innovative treatments could be linked to a drop in patients requiring surgery for a type of inflammatory bowel disease, a 20-year study suggests. The number of patients using ...

People with ulcerative colitis (UC), a chronic inflammatory bowel disease, are up to four times more likely to develop colorectal cancer than the general population. Low-grade dysplasia (LGD)—abnormal ...

Visit our podcast page to listen to "Take What Serves. Leave the Rest" and subscribe using your preferred podcast provider. Learn more at takewhatserves.podbean.com. In this episode, Bryan talks to ...

NEW YORK A new study led by Mayo Clinic researchers found that ulcerative colitis patients had a 41% reduction in colectomy when treated with infliximab for one year, according to a study published in ...

Colitis Symptoms Ulcerative Colitis Symptoms How They Differ Treatment Options Colitis and ulcerative colitis (UC) can look very similar because they share symptoms like abdominal pain, diarrhea, and ...

What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...